INGEBI   02650
INSTITUTO DE INVESTIGACIONES EN INGENIERIA GENETICA Y BIOLOGIA MOLECULAR "DR. HECTOR N TORRES"
Unidad Ejecutora - UE
artículos
Título:
Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
Autor/es:
FERNÁNDEZ, MARISA LILIANA; MASTRANTONIO, GUIDO; RAMIREZ, JUAN CARLOS; ALTCHEH, JAIME; RIARTE, ADELINA ROSA; MARSON, MARIA ELENA; FERNÁNDEZ, MARISA LILIANA; SCHIJMAN, ALEJANDRO GABRIEL; MASTRANTONIO, GUIDO; BOURNISSEN, FACUNDO GARCÍA; RIARTE, ADELINA ROSA; MARSON, MARIA ELENA; SCHIJMAN, ALEJANDRO GABRIEL; BOURNISSEN, FACUNDO GARCÍA; RAMIREZ, JUAN CARLOS; ALTCHEH, JAIME
Revista:
MEMóRIAS DO INSTITUTO OSWALDO CRUZ.
Editorial:
FUNDACO OSWALDO CRUZ
Referencias:
Año: 2016 vol. 111 p. 218 - 221
ISSN:
0074-0276
Resumen:
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/ day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.